Wells Fargo Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $82
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Yanan Zhu has maintained an Overweight rating on Ionis Pharmaceuticals (NASDAQ:IONS) but lowered the price target from $85 to $82.
May 08, 2024 | 2:43 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Wells Fargo maintains an Overweight rating on Ionis Pharmaceuticals but reduces the price target from $85 to $82.
The adjustment in price target by a major analyst like Wells Fargo can influence investor sentiment, but the maintenance of an Overweight rating suggests a continued positive outlook on the stock. The slight reduction in price target may reflect adjustments in valuation models or market conditions, but it's not indicative of a fundamental change in the company's outlook.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100